ApiJect Awarded HHS-DOD Title 3, Defense Production Act (DPA) Contract of $138 Million in Support of a Joint Federal Agency Accelerated Build-out of Domestic Surge Capacity for a High-Speed, Population-Scale Emergency Drug Injection Solution
STAMFORD, Conn., May 12, 2020 /PRNewswire/ -- ApiJect Systems America, Inc., a public benefit corporation based here, today announced that it has been awarded an HHS-DOD Title 3, DPA contract valued up to $138 million to accelerate the building of a new U.S.-based, high-speed, population-scale emergency drug injection capability with prefilled syringes from its subsidiary RAPID Inc.